Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS

Blood

Volumn 98, Issue 8, 2001, Pages 2326-2331

  De Witte, Theo ^a   Suciu, Stefan ^b   Verhoef, Gregor ^c   Labar, Boris ^d   Archimbaud, Eric ^e   Aul, Carlo ^f   Selleslag, Dominique ^g   Ferrant, Augustin ^h   Wijermans, Pierre ⁱ   Mandelli, Franco ^j   Amadori, Sergio ^j   Jehn, Ulrich ^k   Muus, Petra ^a   Boogaerts, Marc ^c   Zittoun, Robert ^l   Gratwohl, Alois ^m   Zwierzina, Heintz ⁿ   Hagemeijer, Anne ^c   Willemze, Roel ^o  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d KBC Zagreb   (Croatia)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g General Hospital St Jan   (Belgium)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ LEYENBURG HOSPITAL   (Netherlands)

^j S EUGENIO HOSPITAL   (Italy)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l HÔTEL DIEU   (France)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW CELL; BONE MARROW HYPOPLASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG FATALITY; FOLLOW UP; HISTOCOMPATIBILITY; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIBLING; SIDE EFFECT; STEM CELL TRANSPLANTATION;

EID: 0035889123     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2326     Document Type: Article

References (26)

1. Mufti GJ, Stevens JR, Oscier DG, et al, Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol. 1985;59:425-433.
2. Bennett JM, Catovsky D, Daniel MD, et al (FAB Co-operative Group). Proposals for the classification of the myetodysplastic syndromes. Br J Haematol. 1982;51:189-199.
3. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4:1748-1757.
4. Yunis JJ, Rydell RE, Arnesen MA, et al. Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndrome. Blood. 1986;67:1721-1730.
5. Geddes A, Bowen D, Jacobs A, Clonal karyotypic abnormalities and clinical progress in the myelodysplastic syndromes. Br J Haematol. 1990;76:194-202.
6. Greenberg P, Cox C, LeBeau M, et al. International workshop risk analysis system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2077-2088.
7. Appelbaum FR, Barrall J, Storb R, et al. Bone marrow transplantation for patients with myelodysplasia. Ann Int Med. 1990;112:590-597.
8. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677-681.
9. De Witte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol. 1990;74:151-157.
10. De Witte T, Muus P, De Pauw, Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer. 1990;66:831-837.
11. De Witte T, Suciu S, Peetermans M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myelogenous leukemia following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment in Cancer. (EORTC-LCG). Leukemia. 1995;9:1805-1811.
12. Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia. Br J Haematol. 1997:99:939-944.
13. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: John Wiley; 1990.
14. Fenaux P, Morel P, Rose C, et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol. 1991;77:497-501.
15. Estey E, Thall P, Beran M. et al. Effect of diagnosis (refractory anemia with excess of blasts, refractory anemia with excess of blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969-2977.
16. Deiforge M, Demuynck H, Vandenberghe P, et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood. 1995;86:3660-3667.
17. Demuynck H, Delforge G, Verhoef P, et al. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol. 1996; 92:351-359.
18. Carella AM, Delana A,. Lerma E, et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukemia. Br J Haematol. 1996;95:127-130.
19. Laporte JP, Isnard F, Lesage S, et al. Autologous bone marrow transplantation with marrow purged by Mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia. 1993;7:2030-2033.
20. Schiller G, Lee M, Paquette R, et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission. Leuk Lymphoma. 1999;33:475-484.
21. , Wattel E, Solary E, Leleu X, et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia, 1999;13:524-529.
22. De Witte T, Van Biezen A, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood. 1997;10:3853-3857.
23. Runde V, De Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical sibling as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant. 1998;21:255-261.
24. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy, Blood. 1997;89:2578-2585.
25. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de-novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood. 1996;88:358-365.
26. De Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2000;110:620-630.